


# Aldeyra Is a Well-Capitalized Biotechnology Company with a Broad Immunology Pipeline



As of 6/30/2025, cash, cash equivalents, and marketable securities were \$81.9M, which Aldeyra believes will be sufficient to fund the Company into the second half of 2027.\*